DK2027152T3 - Peptidfragmenter til induktion af syntese af ekstracellulære matrixproteiner - Google Patents

Peptidfragmenter til induktion af syntese af ekstracellulære matrixproteiner

Info

Publication number
DK2027152T3
DK2027152T3 DK07796001.1T DK07796001T DK2027152T3 DK 2027152 T3 DK2027152 T3 DK 2027152T3 DK 07796001 T DK07796001 T DK 07796001T DK 2027152 T3 DK2027152 T3 DK 2027152T3
Authority
DK
Denmark
Prior art keywords
seq
induction
synthesis
extracellular matrix
peptide fragments
Prior art date
Application number
DK07796001.1T
Other languages
English (en)
Inventor
Scott M Harris
Timothy J Falla
Lijuan Zhang
Original Assignee
Helix Biomedix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helix Biomedix Inc filed Critical Helix Biomedix Inc
Application granted granted Critical
Publication of DK2027152T3 publication Critical patent/DK2027152T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Birds (AREA)
  • Zoology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
DK07796001.1T 2006-06-13 2007-06-12 Peptidfragmenter til induktion af syntese af ekstracellulære matrixproteiner DK2027152T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81328406P 2006-06-13 2006-06-13
PCT/US2007/013748 WO2007146269A2 (en) 2006-06-13 2007-06-12 Peptide fragments for inducing synthesis of extracellular matrix proteins

Publications (1)

Publication Number Publication Date
DK2027152T3 true DK2027152T3 (da) 2012-02-20

Family

ID=38664422

Family Applications (3)

Application Number Title Priority Date Filing Date
DK11175263.0T DK2409988T3 (da) 2006-06-13 2007-06-12 Peptidfragmenter til induktion af syntese af ekstracellulære matrixproteiner
DK07796001.1T DK2027152T3 (da) 2006-06-13 2007-06-12 Peptidfragmenter til induktion af syntese af ekstracellulære matrixproteiner
DK11175264.8T DK2402369T3 (da) 2006-06-13 2007-06-12 Peptidfragmenter til inducering af syntese af ekstracellulære matrixproteiner

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK11175263.0T DK2409988T3 (da) 2006-06-13 2007-06-12 Peptidfragmenter til induktion af syntese af ekstracellulære matrixproteiner

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK11175264.8T DK2402369T3 (da) 2006-06-13 2007-06-12 Peptidfragmenter til inducering af syntese af ekstracellulære matrixproteiner

Country Status (19)

Country Link
US (5) US8110658B2 (da)
EP (5) EP2402369B1 (da)
JP (2) JP5535620B2 (da)
CN (2) CN101472944B (da)
AT (1) ATE533785T1 (da)
AU (1) AU2007258387B2 (da)
BR (2) BRPI0713153B8 (da)
CA (4) CA2835369C (da)
CY (1) CY1112241T1 (da)
DK (3) DK2409988T3 (da)
ES (4) ES2545219T3 (da)
HK (5) HK1210791A1 (da)
HU (2) HUE026698T2 (da)
MX (2) MX2008016011A (da)
PL (4) PL2027152T3 (da)
PT (2) PT2409988E (da)
RU (2) RU2441877C2 (da)
SI (2) SI2027152T1 (da)
WO (1) WO2007146269A2 (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101472944B (zh) * 2006-06-13 2014-05-28 赫里克斯生物医疗公司 用于诱导细胞外基质蛋白合成的肽片段
EP2065029B1 (en) * 2007-11-30 2013-04-17 Evonik Goldschmidt GmbH Personal care and cosmetic composition containing tetrapeptides with the motifs GX1X2G, PX1X2P, or PX1X2K
WO2009111471A2 (en) * 2008-03-03 2009-09-11 Henry Ford Health System Collagen-derived peptide as biomarker, therapeutic agent and target
EP2235038B1 (de) * 2008-12-30 2019-06-05 GKL-Biotec AG Tetrapeptidkombination
WO2011044443A2 (en) * 2009-10-09 2011-04-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Matricryptic ecm peptides for tissue reconstruction
US8969290B2 (en) 2012-06-26 2015-03-03 Worcester Polytechnic Institute Matrix scaffold with antimicrobial activity
SI2956155T1 (sl) * 2013-02-14 2017-10-30 Helix Biomedix Inc. Kratki bio aktivni peptidi za spodbujanje celjenja ran
CN105189531B (zh) 2013-03-13 2020-02-21 安特易斯有限公司 用于皮肤复新的肽及其使用方法
US10392611B2 (en) 2013-05-30 2019-08-27 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
US10364451B2 (en) 2013-05-30 2019-07-30 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
CN105324122B (zh) * 2013-06-14 2019-08-27 赫里克斯生物医疗公司 可用于治疗多种皮肤病的衍生自人类c-x-c趋化因子的四肽
WO2016154530A1 (en) 2015-03-26 2016-09-29 Duke University Targeted therapeutic agents comprising multivalent protein-biopolymer fusions
JP6882782B2 (ja) 2015-08-04 2021-06-02 デューク ユニバーシティ 遺伝子コードされた本質的に無秩序な送達用ステルスポリマーおよびその使用方法
KR101916522B1 (ko) 2015-09-25 2018-11-08 경상대학교산학협력단 굴 가수분해물의 제조방법 및 이로부터 분리된 펩타이드
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
CN109890833A (zh) 2016-09-14 2019-06-14 杜克大学 用于递送亲水性药物的基于三嵌段多肽的纳米粒子
US11155584B2 (en) 2016-09-23 2021-10-26 Duke University Unstructured non-repetitive polypeptides having LCST behavior
US11648200B2 (en) 2017-01-12 2023-05-16 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
JP6489486B2 (ja) * 2017-01-20 2019-03-27 富比積生物科技股▲分▼有限公司 ペンタペプチド／ヘキサペプチドにより変形性関節症を治療するための新規用途
JP6489487B2 (ja) * 2017-01-20 2019-03-27 富比積生物科技股▲分▼有限公司 テトラペプチド−３ ｇｅｋｇまたはペンタペプチド−３ ｇｅｋｇｆにより変形性関節症を治療するための新規用途
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
WO2019006374A1 (en) 2017-06-30 2019-01-03 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-SENSITIVE BIOPOLYMER NETWORKS
EP3829622A4 (en) 2018-08-02 2022-05-11 Duke University DUAL AGONIST FUSION PROTEINS
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
EP4000598A1 (en) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptide and compositions comprising tetrapeptides
EP4000596A1 (en) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptide and compositions comprising tetrapeptides
EP4000595A1 (en) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptide and compositions comprising tetrapeptides
EP4000597A1 (en) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptide and compositions comprising tetrapeptides
EP4140473A1 (en) * 2021-08-27 2023-03-01 The Boots Company plc Cosmetic compositions
CN114437238B (zh) * 2022-01-26 2024-03-26 浙江工业大学 胶原蛋白肽-牛乳铁蛋白肽融合蛋白、基因及其表达方法
CN116375847A (zh) * 2022-10-26 2023-07-04 江苏创健医疗科技股份有限公司 酵母重组xvii型人源化胶原蛋白及其制备方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU466760B2 (en) * 1972-03-14 1975-11-06 Takeda Chemical Industries Ltd. Process for producing peptide
US5064430A (en) * 1985-10-31 1991-11-12 Uab Research Foundation Polynonapeptide bioelastomers having an increased elastic modulus
JP2573006B2 (ja) * 1987-12-17 1997-01-16 富士薬品工業株式会社 新規なヒドロキサム酸誘導体
ATE111715T1 (de) 1988-04-21 1994-10-15 Uab Research Foundation Bioelastomer ohne adhäsionseigenschaft zum einsatz am wundort.
DE69034085T2 (de) 1989-04-10 2004-05-27 Helix BioMedix, Inc., Bothell Lytsche und proliferative Peptide und deren Verwendung als Pharmaka und Phytopharmaka
US5679770A (en) * 1991-11-08 1997-10-21 Mochida Pharmaceutical Co., Ltd. Polypeptide, DNA fragment encoding the same, drug composition containing the same and process for producing the same
JP3100005B2 (ja) * 1992-07-28 2000-10-16 雪印乳業株式会社 ヒト免疫不全ウィルス感染・増殖抑制剤
US6132976A (en) * 1992-12-04 2000-10-17 Shriners Hospitals For Children Immunoassays for the measurement of collagen denaturation and cleavage in cartilage
IL104954A (en) * 1993-03-04 2006-08-01 Yissum Res Dev Co Use of osteogenic oligopeptides in the preparation of pharmaceutical compositions for the treatment of bone diseases and some such novel oligopeptides, pharmaceutical compositions containing them and their preparation
US5561107A (en) 1993-06-04 1996-10-01 Demeter Biotechnologies, Ltd. Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides
JPH07227281A (ja) * 1994-02-15 1995-08-29 Agency Of Ind Science & Technol ペプチダーゼ及びその製造法
US5763576A (en) * 1995-10-06 1998-06-09 Georgia Tech Research Corp. Tetrapeptide α-ketoamides
US6159940A (en) * 1996-02-28 2000-12-12 Immunotech Developments Inc. Method for modulating hemopoiesis
DE19651099A1 (de) * 1996-12-09 1998-06-10 Consortium Elektrochem Ind Mehrkomponentensystem zum Verändern, Abbau oder Bleichen von Lignin, ligninhaltigen Materialien oder ähnlichen Stoffen sowie Verfahren zu seiner Anwendung
EP1074620A1 (en) * 1999-08-06 2001-02-07 HyGene AG Monomeric protein of the TGF-beta family
EP0858808B1 (en) * 1997-01-17 2003-04-02 Johnson & Johnson Medical Ltd. Peptides for use in wound treatment
US6639050B1 (en) * 1997-07-21 2003-10-28 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
GB2341182A (en) * 1998-09-01 2000-03-08 Yamanouchi Uk Ltd Protein comprising amino acid sequences having SH3 domain binding activity and nuclear localisation activity
US6747135B1 (en) * 1998-10-16 2004-06-08 The Board Of Trustees For The Leland Stanford Junior University Fluorescent dye binding peptides
US6492326B1 (en) * 1999-04-19 2002-12-10 The Procter & Gamble Company Skin care compositions containing combination of skin care actives
CA2276542C (en) * 1999-06-28 2013-07-30 Vladislav I. Deigin Novel peptide, a method for its preparation and a pharmaceutical composition containing the peptide
CN1280983A (zh) * 1999-07-16 2001-01-24 王革 白细胞介素－11的衍生物及其制备方法
US6627785B1 (en) * 2000-02-29 2003-09-30 Virginia Commwealth University Wound dressings with protease-lowering activity
AU2001255448A1 (en) * 2000-04-17 2001-10-30 Stephen B. Liggett Alpha-2 adrenergic receptor polymorphisms
US20030166510A1 (en) * 2000-10-11 2003-09-04 Pickart Loren R. Methods and compositions for increasing skin remodeling
GB0029777D0 (en) * 2000-12-06 2001-01-17 Regen Therapeutics Plc Peptides
EP1379265A4 (en) 2001-03-28 2005-09-14 Helix Biomedix Inc SHORT BIOACTIVE PEPTIDES AND METHODS OF USE
US7186693B2 (en) * 2001-08-16 2007-03-06 Kimberly - Clark Worldwide, Inc. Metalloproteinase inhibitors for wound healing
US7041506B2 (en) * 2001-11-19 2006-05-09 Becton Dickinson And Company Peptides promoting cell adherence, growth and secretion
JP2005519587A (ja) * 2001-11-28 2005-07-07 ベクトン・ディキンソン・アンド・カンパニー 増殖阻害作用を有するペプチド
WO2003064620A2 (en) * 2002-01-31 2003-08-07 Irm, Llc Hepsin substrates and prodrugs
EP1504033A2 (en) * 2002-05-03 2005-02-09 Millenium Biologix Inc. Connective tissue stimulating peptides
EP1576352B1 (en) * 2002-09-09 2010-04-14 University Of Cincinnati Methods of cardiovascular disease assessment in an individual
US7541440B2 (en) * 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
TWI256893B (en) * 2003-03-25 2006-06-21 Fancl Corp Composition for promoting production of type I collagen and/or elastin
DE10339180A1 (de) * 2003-08-21 2005-03-24 Deutsche Gelatine-Fabriken Stoess Ag Kollagenhydrolysat
US7638318B2 (en) 2003-09-26 2009-12-29 Norvartis Ag Seneca Valley virus based compositions and methods for treating disease
ATE548022T1 (de) 2003-11-17 2012-03-15 Sederma Sa Zusammensetzungen mit einer kombination von tetrapeptiden und tripeptiden
JP2005245285A (ja) * 2004-03-03 2005-09-15 National Institute Of Advanced Industrial & Technology コラーゲン分解物の製造方法
DE102005000868A1 (de) * 2004-10-15 2006-04-20 Henkel Kgaa Zusammensetzungen mit Inhibitoren der Prostaglandin- und/oder Leukotrien-Synthese in Kombination mit Stimulatoren der Freisetzung kutaner Neuromediatoren
DE102004050563A1 (de) * 2004-10-15 2006-04-20 Henkel Kgaa Kosmetische und der dermatologische Zusammensetzungen mit Wirkstoffen für einen verbesserten Hautkomfort
DE102004055541A1 (de) * 2004-11-17 2006-05-18 Henkel Kgaa Kosmetische und dermatologische Zusammensetzungen zur Behandlung reifer Haut
DE202004012807U1 (de) * 2004-08-13 2004-10-21 Henkel Kgaa Kosmetische und dermatologische Zusammensetzungen mit DNA-Reparaturenzymen und Oligopeptiden
WO2006028993A2 (en) * 2004-09-02 2006-03-16 Vanderbilt University Assessment of cancer susceptibility to molecular targeted therapy by use of recombinant peptides
WO2006041933A2 (en) * 2004-10-05 2006-04-20 Diversa Corporation Improved vaccines
ES2426441T3 (es) * 2004-10-18 2013-10-23 Basf Beauty Care Solutions France S.A.S. Oligopéptidos y su uso en cosméticos
WO2006048339A2 (en) * 2004-11-04 2006-05-11 L'oréal Cosmetic composition comrising an active agent and a urea compound
US20070224150A1 (en) * 2005-03-24 2007-09-27 Yongji Chung Growth factor for hair and skin treatment
FR2884418B1 (fr) * 2005-04-15 2008-11-21 Soc Extraction Principes Actif Utilisation d'un peptide comme principe actif amincissant
JP4846799B2 (ja) * 2005-07-05 2011-12-28 バイオテンプト ベー．フェー． 腫瘍の治療
DE102005063062A1 (de) * 2005-12-29 2007-07-05 Henkel Kgaa Synergistische Proteinhydrolysat-Kombinationen zur Behandlung reifer Haut
US7807625B2 (en) * 2006-01-18 2010-10-05 Grant Industries, Inc Anti-wrinkle composition
CN101472944B (zh) * 2006-06-13 2014-05-28 赫里克斯生物医疗公司 用于诱导细胞外基质蛋白合成的肽片段

Also Published As

Publication number Publication date
HUE026698T2 (en) 2016-07-28
EP3002294A2 (en) 2016-04-06
US20120093740A1 (en) 2012-04-19
US20140066380A1 (en) 2014-03-06
HUE027273T2 (en) 2016-10-28
ES2375413T3 (es) 2012-02-29
ES2545219T3 (es) 2015-09-09
WO2007146269A2 (en) 2007-12-21
EP3002294B8 (en) 2018-05-16
US8110658B2 (en) 2012-02-07
JP2014129369A (ja) 2014-07-10
BR122018002612B1 (pt) 2021-01-19
MX361694B (es) 2018-12-10
ES2680022T3 (es) 2018-09-03
HK1210791A1 (en) 2016-05-06
PL2409988T3 (pl) 2015-12-31
EP2940042A3 (en) 2016-02-17
US9447143B2 (en) 2016-09-20
EP2940042A2 (en) 2015-11-04
EP2402369B1 (en) 2015-11-25
US20070299015A1 (en) 2007-12-27
CN101472944A (zh) 2009-07-01
EP3002294A3 (en) 2016-06-22
CY1112241T1 (el) 2015-12-09
RU2009100884A (ru) 2010-07-20
RU2501807C2 (ru) 2013-12-20
US10376557B2 (en) 2019-08-13
DK2402369T3 (da) 2016-02-01
DK2409988T3 (da) 2015-09-14
CA2947349A1 (en) 2007-12-21
CN101472944B (zh) 2014-05-28
EP2402369A2 (en) 2012-01-04
HK1217346A1 (zh) 2017-01-06
EP2409988A3 (en) 2012-05-09
AU2007258387A1 (en) 2007-12-21
CA2655116C (en) 2016-12-13
HK1128700A1 (en) 2009-11-06
PL2027152T3 (pl) 2012-04-30
JP5844834B2 (ja) 2016-01-20
CA2835369C (en) 2017-01-31
CN104017071A (zh) 2014-09-03
EP2409988B1 (en) 2015-07-22
EP3002294B1 (en) 2018-03-28
HK1161600A1 (zh) 2012-07-27
EP2027152A2 (en) 2009-02-25
BR122018002612B8 (pt) 2021-07-27
PT2402369E (pt) 2016-02-19
RU2011141572A (ru) 2013-04-20
CA2655116A1 (en) 2007-12-21
US20150094270A1 (en) 2015-04-02
CA2947353A1 (en) 2007-12-21
JP5535620B2 (ja) 2014-07-02
BRPI0713153B1 (pt) 2019-05-14
PT2409988E (pt) 2015-10-12
MX2008016011A (es) 2009-02-13
ATE533785T1 (de) 2011-12-15
CA2835369A1 (en) 2007-12-21
AU2007258387B2 (en) 2012-08-16
BRPI0713153A2 (pt) 2012-03-27
EP2409988A2 (en) 2012-01-25
EP2027152B1 (en) 2011-11-16
SI2027152T1 (sl) 2012-03-30
AU2007258387A2 (en) 2009-02-19
SI2409988T1 (sl) 2015-10-30
PL2402369T3 (pl) 2016-05-31
RU2441877C2 (ru) 2012-02-10
US8962798B2 (en) 2015-02-24
ES2557402T3 (es) 2016-01-25
US8658764B2 (en) 2014-02-25
EP2402369A3 (en) 2012-05-16
CN104017071B (zh) 2017-08-15
BRPI0713153B8 (pt) 2021-05-25
HK1161599A1 (en) 2012-07-27
JP2009539987A (ja) 2009-11-19
WO2007146269A3 (en) 2008-08-14
US20170157196A1 (en) 2017-06-08
PL3002294T3 (pl) 2018-08-31

Similar Documents

Publication Publication Date Title
DK2027152T3 (da) Peptidfragmenter til induktion af syntese af ekstracellulære matrixproteiner
BR112012017345A2 (pt) "composições e métodos de pgl para a produção aumentada de isopreno e outros produtos com 6-fosfogliconolactonase (pgl)"
UA117216C2 (uk) Пухлиноасоційований пептид та його застосування
MX2009010610A (es) Dominio de enlace especifico de especies cruzadas.
BR0208150A (pt) Antagonistas de mch e sua aplicação no tratamento da obesidade
RS54215B1 (en) COMPOSITIONS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER
RS54204B1 (en) NEW IMMUNOTHERAPY AGAINST BRAIN TUMOR
DE602004001727D1 (de) Verfahren zur herstellung cyclischer peptide
CL2007001710A1 (es) Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras.
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
ECSP099341A (es) Nuevos anticuerpos antiproliferativos
ATE443722T1 (de) Peptide und peptidderivate, ihre herstellung sowie ihre verwendung zur herstellung einer therapeutisch und/oder prophylaktisch wirksamen pharmazeutischen zusammensetzung
NZ596501A (en) Casb7439 constructs
EA200801077A1 (ru) Антагонисты взаимодействия pf4 и rantes
RS52448B (en) ANTITUMOR PHARMACEUTICAL COMPOSITION CONTAINING SERALIZIN POLYPEPTIDE FRAGMENTS
NZ589743A (en) Anxiolytic composition containing alphas1-casein-derived peptides
GB201018125D0 (en) Peptide
MX2010005597A (es) Péptidos inmunoreguladores novedosos, composiciones y usos de los mismos.
ATE544779T1 (de) Neue, die migration dendritischer zellen induzierende polypeptide, sowie medikamente und pharmazeutische zusammensetzungen, die diese enthalten
ATE452141T1 (de) Neue proteine, z.b. zur verwendung für die in- vitro-isolierung und prävention von legionella pneumophila-infektionen
CY1117084T1 (el) Θραυσματα πεπτιδιου για την επαγωγη συνθεσης πρωτεϊνων εξωκυτταριας μητρας
UA95456C2 (ru) Взаимодействие moraxella catarrhalis с эпителиальными клетками, внеклеточными матриксными белками и системой комплемента
NZ593774A (en) Systems and methods for identifying Replikin scaffolds and uses of said Replikin scaffolds